Lilly Features it's Rheumatoid and Psoriasis Biologics at ACR 2016 Save

Eli Lilly & Co. has multiple presentations planned for the upcoming Annual meeting of the ACR/ARHP in Washington starting on Sunday, November 13th.

On Baricitinib and Ixekizumab (Taltz) there will be 23 presentations, including the results of the pivotal BEACON study (in DMARD-IR RA patients) and a combined post hoc analysis of the baricitinib safety portfoliio.  Also being presented will be data on Taltz (ixekizumab) its anti-IL-17 monoclonal antibody that is FDA approved for use in chronic plaque psoriasis.

BARICITINIB

Sunday, November 13, 2016, 9:00am - 11:00am EST - POSTER PRESENTATIONS

• Biologic Initiation Patterns Among Rheumatoid Arthritis Patients in Moderate or High Disease Activity While Using Conventional Disease Modifying Anti-Rheumatic Drugs (Presenting Author: Boytsov, N.) Abstract Number: 637
• Drivers of the SLE Responder Index (SRI) Endpoint in Clinical Trials of SLE (Presenting Author: Kalunian, K.) Abstract Number: 784

Monday, November 14, 2016, 9:00am - 11:00am EST - POSTER PRESENTATIONS

• Baricitinib Exposure-Efficacy Relationship in Rheumatoid Arthritis Patients from Integrated Analyses of Phase 2 and Phase 3 Studies (Presenting Author: Ernest, C.) Abstract Number: 1584
• Previous Use of Conventional Disease-Modifying Antirheumatic Drugs and Response to Baricitinib (Presenting Author: Kavanaugh, A.) Abstract Number: 1585
• Efficacy and Safety of Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs: A United States Subpopulation Analysis from Two Phase 3 Trials (Presenting Author: Wells, A.) Abstract Number: 1586
• Safety and Efficacy of Baricitinib in Elderly Patients with Moderate to Severe Rheumatoid Arthritis (Presenting Author: Fleischmann, R.) Abstract Number: 1590
• Efficacy and Safety of Switching from Adalimumab to Baricitinib: Phase 3 Data in Patients with Rheumatoid Arthritis (Presenting Author: Taylor, P.) Abstract Number: 1591
• Speed of Onset of Effect on Patient-Reported Outcomes Assessed through Daily Electronic Patient Diaries in the Baricitinib Phase 3 RA Clinical Program (Presenting Author: Taylor, P.) Abstract Number: 1599
• Effect of BMI on Baricitinib Efficacy: Pooled Analysis from Two Phase 3 Rheumatoid Arthritis Clinical Trials (Presenting Author: Zerbini, C.) Abstract Number: 1640

Tuesday, November 15, 2016, 9:00am - 11:00am EST - POSTER PRESENTATIONS

• Biologic DMARD Use Among U.S. Patients in an Online Rheumatoid Arthritis Community (Presenting Author: Chang, L.) Abstract Number: 2237
• RA Medication Preferences Among U.S. Patients in an Online Rheumatoid Arthritis Community (Presenting Author: Zhu, B.) Abstract Number: 2238
• DMARD, Biologic and Small Molecule Drug Use Among ACPA Positive and ACPA Negative RA Patients in a Tertiary Referral Center (Presenting Author: Meehan, R.) Abstract Number: 2496
• Prevalence of Anemia Among Rheumatoid Arthritis Patients Treated With Conventional Disease-Modifying Antirheumatic Drugs (Presenting Author: Kay, J.) Abstract Number: 2584
• Effects of Baseline Patient Characteristics on Baricitinib Efficacy in Patients with Rheumatoid Arthritis (Presenting Author: Kremer, J.) Abstract Number: 2632

Tuesday, November 15, 2016, 2:30pm - 4:30pm EST - ORAL PRESENTATIONS

• A Molecular Signature Based on IFN Gene Signature and Serology Defines Two Populations of Patients with Different Baseline Disease Activity in a Large Multinational Phase 3 SLE Trial Population (Presenting Author: Petri, M.) Abstract Number: 2991
• Lipid Profile and Effect of Statin Treatment in Pooled Phase 2 and Phase 3 Baricitinib Studies (Presenting Author: McInnes, I.) Abstract Number: 3023
• Herpes Zoster in Patients with Moderate to Severe Rheumatoid Arthritis Treated with Baricitinib (Presenting Author: Winthrop, K.) Abstract Number: 3027

TALTZ (Ixekizumab) Data

Sunday, November 13, 2016, 2:30pm - 4:00pm EST - ORAL PRESENTATION

• Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52 week Results from a Phase 3 Study (Presenting Author: Mease, P.) Abstract Number: 959

Monday, November 14, 2016, 9:00am - 11:00am EST - POSTER PRESENTATIONS

• Association of Early Skin Improvement with ACR Responses Among Biologic DMARD-Naive Psoriatic Arthritic Patients Treated with Ixekizumab (Presenting Author: Birt, J.) Abstract Number: 1686
• Effect of Concomitant Conventional Disease-Modifying Antirheumatic Drugs (DMARDs) on the Efficacy and Safety of Ixekizumab in Biologic DMARD-Naive Patients with Active Psoriatic Arthritis (Presenting Author: Lin, C.) Abstract Number: 1687
• Ixekizumab Provides Sustained Improvement up to 52 Weeks of Disease Activity as Assessed by Composite Measure Scores in Biologic Disease-Modifying Antirheumatic Drug -Naive Patients with Active Psoriatic Arthritis (Presenting Author: Coates, L.) Abstract Number: 1688
• Ixekizumab Provides Improvements Through 52 Weeks in Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis (Presenting Author: Gladman, D.) Abstract Number: 1689
• Sustained Efficacy of Ixekizumab in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Psoriatic Arthritis (Presenting Author: Burge, R.) Abstract Number: 1733